Nutcracker Therapeutics, Inc., an Emeryville, Calif.-based company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, raised $60m in Series B financing.
The round was led by Arch Venture Partners with participation from Bluebird Ventures, a firm associated with Sutter Hill Ventures.
The company intends to use the funds to continue to expand its development efforts.
Led by Igor Khandros, Ph.D., co-founder and chief executive officer, who previously founded three publicly traded companies including FormFactor, Inc., and Berkeley Lights, Nutcracker has combined the productivity of RNA biology with innovations inspired by semiconductor manufacturing techniques to develop a proprietary miniaturized platform that enables the rapid discovery, development and manufacturing of mRNA therapies and vaccines.
The ACORN platform is a computer-controlled RNA manufacturing system that starts with a nucleic acid sequence of interest and produces optimized nanoparticle-encapsulated RNA therapeutics on dedicated, single-use biochips.